A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder - MK-0594 Overactive Bladder Dose-Ranging Study

Phase 1

• Conditions: Overactive Bladder; MedDRA version: 8.0 Level: LLT Classification code 10059617

• Registration Number: EUCTR2005-005606-23-DK
• Lead Sponsor: Merck & Co. Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-01-27
• Study Completion: 2007-08-17
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 530

Inclusion Criteria

Postmenopausal women or men aged 40 to 74 (inclusive). Up to 10% of patients will be male. Average of = 8 micturitions per day, average of = 1 urge incontinence episodes per day, and predominance of urge incontinence episodes over stress incontinence episodes on 2 pre-randomization voiding diaries.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

History of diabetes insipidus, uncotrolled hyperglycemia or hypercalcemia, lower urinary tract symptoms associated with benign prostatic hypertrophy, active or current UTI, surgery to correct prolapsed uterus or stress incontinence.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified